Literature DB >> 9719050

Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats.

W C Huang1, T C Fang, J T Cheng.   

Abstract

Experiments were performed to evaluate the role of the renal nerves in hyperinsulinemia-induced hypertension. Male Sprague-Dawley rats were made hyperinsulinemic by insulin infusion via osmotic minipumps implanted subcutaneously (3.0 mU/kg per minute for 6 weeks). Rats with vehicle infusion served as controls. Bilateral renal denervation was performed either at the beginning of or 4 weeks after insulin infusion. The systolic blood pressure was measured by the tail-cuff method twice a week. Food and water intake and urine flow were measured daily. The results showed that sustained insulin infusion significantly increased plasma insulin concentrations from 277.7+/-25.8 pmol/L to 609.9+/-22.2 and 696.7+/-23.0 pmol/L by the end of weeks 4 and 6, respectively (P<0.05). Systolic blood pressure was significantly increased from 135+/-3 to 157+/-3 and 159+/-2 mm Hg (P<0.05) at the corresponding time points. There was a significant increase in the plasma norepinephrine concentration after insulin infusion, whereas no significant changes in plasma triglyceride and glucose concentrations, water intake, urine flow, sodium excretion, sodium gain, and body weight gain were observed. Bilateral renal denervation depleted renal norepinephrine stores and prevented the development of hyperinsulinemia-induced hypertension. After hyperinsulinemia-induced hypertension had been fully established (from 134+/-2 to 157+/-2 mm Hg), bilateral renal denervation reversed the elevated systolic blood pressure to normotensive levels within 2 weeks. Transient denervated diuresis and natriuresis were observed. These results indicate that chronic hyperinsulinemia-induced hypertension requires the presence of intact renal nerves in rats.

Entities:  

Mesh:

Year:  1998        PMID: 9719050     DOI: 10.1161/01.hyp.32.2.249

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

Review 1.  New developments in mechanisms of obesity-induced hypertension: role of adipose tissue.

Authors:  A M Sharma; S Engeli; T Pischon
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 2.  Renal sympathetic denervation: applications in hypertension and beyond.

Authors:  Michael Böhm; Dominik Linz; Daniel Urban; Felix Mahfoud; Christian Ukena
Journal:  Nat Rev Cardiol       Date:  2013-06-18       Impact factor: 32.419

3.  Renal denervation attenuates progression of atherosclerosis in apolipoprotein E-deficient mice independent of blood pressure lowering.

Authors:  Hui Wang; Jintao Wang; Chiao Guo; Wei Luo; Kyle Kleiman; Daniel T Eitzman
Journal:  Hypertension       Date:  2015-02-02       Impact factor: 10.190

Review 4.  Renal Denervation: Where to Now?

Authors:  Neil J Wimmer; Laura Mauri
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

Review 5.  Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?

Authors:  Venkatesh K Raman; Costas Tsioufis; Michael Doumas; Vasilios Papademetriou
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-05

Review 6.  Hypertension and the cardiometabolic syndrome.

Authors:  Camila Manrique; Guido Lastra; Adam Whaley-Connell; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

Review 7.  Renal Denervation: A Potential Novel Treatment for Type 2 Diabetes Mellitus?

Authors:  Tao Pan; Jin-he Guo; Gao-jun Teng
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

8.  ACE gene dosage determines additional autonomic dysfunction and increases renal angiotensin II levels in diabetic mice.

Authors:  Oscar Albuquerque de Moraes; Karin Flues; Kátia Bilhar Scapini; Cristiano Mostarda; Fabiana de Sant'Anna Evangelista; Bruno Rodrigues; Daniela Ravizzoni Dartora; Patricia Fiorino; Kátia De Angelis; Maria Cláudia Irigoyen
Journal:  Clinics (Sao Paulo)       Date:  2018-08-02       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.